SM
ITRM

Sabby Management’s Iterum Therapeutics ITRM Stock Holding History

Sabby Management’s Portfolio ITRM Stock Details ITRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-430,761
Closed -$429K – 53
2025
Q2 		$429K Buy
+430,761
New +$449K 0.78% 17
2023
Q3 		– Sell
-75,000
Closed -$1.13M – 98
2023
Q2 		$1.13M Buy
+75,000
New +$83K 0.92% 9

Other funds holding ITRM

Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
AF
Apollon Financial Mount Pleasant, South Carolina $848M AUM 27.31% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $11.8B AUM 21.23% 1-Year Est. Return
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors Raleigh, North Carolina $65.5B AUM 24.25% 1-Year Est. Return
GWP
Gen-Wealth Partners Zeeland, Michigan $360M AUM 27.44% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
KF
Krilogy Financial St. Louis, Missouri $3.38B AUM 30.57% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $21.6B AUM 28.31% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

Sabby Management's ITRM Position: Q3 2025 in Review

Sabby Management sold out of Iterum Therapeutics (ITRM) in Q3 2025, closing a stake of 430,761 shares — an estimated $429K sold.

Sabby Management first reported a position in ITRM in Q2 2023 and held it in 2 quarters. The position peaked at $1.13M in Q2 2023. 24 funds tracked by Wall St. Rank hold ITRM as of Q3 2025.

  • Sabby Management reported no remaining Iterum Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Sabby Management sold 430,761 Iterum Therapeutics shares in Q3 2025, an estimated $429K.
  • Sabby Management first reported a position in Iterum Therapeutics in Q2 2023 and held it in 2 quarters.
  • Sabby Management's Iterum Therapeutics position peaked at $1.13M in Q2 2023.
  • 24 funds tracked by Wall St. Rank held Iterum Therapeutics as of Q3 2025.

Based on Sabby Management's 13F filing for Q3 2025, filed 14 Nov 2025.